Literature DB >> 23879870

Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.

Richard B Lipton1, Dawn C Buse, Daniel Serrano, Starr Holland, Michael L Reed.   

Abstract

BACKGROUND: Despite the expanding therapeutic armamentarium, many people with episodic migraine (EM) have unmet acute treatment needs.
OBJECTIVE: To determine the relative frequency of prespecified types of "unmet treatment needs" in persons with EM in a US population-based sample.
METHODS: Eligible participants completed the 2009 American Migraine Prevalence and Prevention Study survey and met International Classification of Headache Disorders-2nd edition (ICHD-2) criteria for migraine with an average headache day frequency of <15 days per month (EM). We identified 5 domains of unmet treatment needs: (1) dissatisfaction with current acute treatment using 3 summary items from the Patient Perception of Migraine Questionnaire-revised edition (PPMQ-R); (2) moderate or severe headache-related disability defined by a Migraine Disability Assessment Scale score of ≥11; (3) excessive use of opioids or barbiturates defined as use on ≥4 days/month or by meeting Diagnostic and Statistical Manual for Mental Disorders-4th edition criteria for dependence; (4) recurrent use of the emergency department or urgent care clinic for headache defined by ≥2 visits in the preceding year for headache; and (5) history of cardiovascular events indicating a possible contraindication to triptan use. For each respondent, we identified their unmet treatment needs in each category and classified them as having no unmet needs or 1 or more unmet needs.
RESULTS: Of 5591 respondents with EM, 2274 (40.7%) had 1 or more unmet needs; 1467 (26.2%) had exactly 1 unmet need, and 807 (14.4%) had 2 or more unmet needs. Among those with at least 1 unmet need, 1069 (47.0%) had moderate or severe headache-related disability, 851 (37.4%) were dissatisfied with their acute treatment regimen, 728 (32.0%) had excessive opioid or barbiturate use and/or probable dependence, 595 (26.2%) had a history of cardiovascular events, and 129 (5.7%) reported ≥2 visits in the preceding year to the emergency department/urgent care clinic for headache. Persons with more headache days, depression, or generalized anxiety were more likely to have unmet treatment needs.
CONCLUSION: In a population sample of individuals with EM, more than 40% have at least 1 unmet need in the area of acute treatment. The leading reasons for unmet needs, which include headache-related disability and dissatisfaction with current acute treatment, suggest opportunities for improving outcomes for persons with EM.
© 2013 American Headache Society.

Entities:  

Keywords:  acute treatment; cardiovascular risk factors; headache-related disability; migraine; satisfaction; unmet need

Mesh:

Year:  2013        PMID: 23879870     DOI: 10.1111/head.12154

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  40 in total

1.  Quality improvement in neurology: primary headache quality measures.

Authors:  Stephen Ross; Eric Wall; Becky Schierman; J Mark Bailey; Eric Cheng; Charles Flippen; Shannon Petersen; Amy Sanders; David Seidenwurm; M Cristina Victorio
Journal:  Neurology       Date:  2015-01-13       Impact factor: 9.910

Review 2.  Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experience.

Authors:  Shivang Joshi; Alan M Rapoport
Journal:  Ther Adv Neurol Disord       Date:  2017-02-08       Impact factor: 6.570

3.  The Impact of Post-Traumatic Stress Disorder on the Burden of Migraine: Results From the National Comorbidity Survey-Replication.

Authors:  Aruna S Rao; Ann I Scher; Rebeca V A Vieira; Kathleen R Merikangas; Andrea L Metti; B Lee Peterlin
Journal:  Headache       Date:  2015-10-16       Impact factor: 5.887

4.  The Impact of Spinal Manipulation on Migraine Pain and Disability: A Systematic Review and Meta-Analysis.

Authors:  Pamela M Rist; Audrey Hernandez; Carolyn Bernstein; Matthew Kowalski; Kamila Osypiuk; Robert Vining; Cynthia R Long; Christine Goertz; Rhayun Song; Peter M Wayne
Journal:  Headache       Date:  2019-03-14       Impact factor: 5.887

Review 5.  The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.

Authors:  Uwe Reuter; Heike Israel; Lars Neeb
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

6.  Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.

Authors:  Richard B Lipton; David W Dodick; Jessica Ailani; Kaifeng Lu; Michelle Finnegan; Armin Szegedi; Joel M Trugman
Journal:  JAMA       Date:  2019-11-19       Impact factor: 56.272

7.  A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation.

Authors:  K Hoehlig; K W Johnson; E Pryazhnikov; C Maasch; A Clemens-Smith; W G Purschke; S Vauléon; K Buchner; F Jarosch; L Khiroug; A Vater; S Klussmann
Journal:  Br J Pharmacol       Date:  2015-03-27       Impact factor: 8.739

8.  The development of a mouse model of mTBI-induced post-traumatic migraine, and identification of the delta opioid receptor as a novel therapeutic target.

Authors:  Laura S Moye; Madeline L Novack; Alycia F Tipton; Harish Krishnan; Subhash C Pandey; Amynah Aa Pradhan
Journal:  Cephalalgia       Date:  2018-05-17       Impact factor: 6.292

Review 9.  Forecasting Migraine Attacks and the Utility of Identifying Triggers.

Authors:  Dana P Turner; Adriana D Lebowitz; Ivana Chtay; Timothy T Houle
Journal:  Curr Pain Headache Rep       Date:  2018-07-16

10.  Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea.

Authors:  Byung-Kun Kim; Min Kyung Chu; Soo Jin Yu; Grazia Dell'Agnello; Jeong Hee Han; Soo-Jin Cho
Journal:  J Headache Pain       Date:  2021-05-24       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.